February 10, 2014
FOR IMMEDIATE RELEASE [Cincinnati, OH ~ February 10, 2014] CTI Clinical Trial and Consulting Services (CTI) will be one of the sponsors of the 9th Annual New York Stem Cell Summit, taking place February 18, 2014. The faculty will include more than 30 of the world’s leaders in the stem cell and regenerative medicine industry to discuss investment opportunities, groundbreaking products, and the growing potential in the marketplace.
Additionally, CTI CEO, Timothy J. Schroeder, will present on the topic “Cutting Time to Market for Stem Cell Suppliers”. According to Mr. Schroeder, “This is the critical driver for shareholders in the pharmaceutical and biotechnology industry. Many delays can be avoided or minimized with an experienced team. As more regenerative medicine programs advance in the clinic, important expertise has been gained including regulatory and clinical knowledge that results in both cost and time efficiencies.”
Mr. Schroeder founded CTI fifteen years ago, and is internationally recognized in the field of transplantation and regenerative medicine. Throughout his more than 30 years of clinical, academic, and industry experience, he has authored over 200 peer reviewed publications and has presented more than 300 papers at national and international conferences. He has served as a visiting lecturer on more than 200 occasions.
Mr. Schroeder adds, “CTI is happy to be a part of an event involving thought leaders in stem cell and regenerative medicine. Our sponsorship demonstrates our commitment to this field, which will revolutionize the treatment of many diseases, and our appreciation to Robin Young, CFA, and RRY Publications, LLC for leading this groundbreaking conference.”
About CTI Clinical Trial and Consulting Services
CTI Clinical Trial and Consulting Services is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consulting services from bench to commercialization with a focus on immunology and a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology and startup firms with clinical and disease area expertise from a unique mix of academic, medical and industry specialists; rich intellectual capital in transplantation, immunology, infectious diseases, hematology, cardiology, nephrology, hepatology, regenerative medicine and rare diseases; flexible study designs that accelerate development programs and deliver high approval ratings that are among the best in the industry; and exceptional global project management and gold standard safety and data management systems that strengthen their program’s success potential. Established in 1999 and headquartered in Cincinnati, OH; CTI has offices in North America, Europe and South America.